PAVmed (PAVM) Net Income towards Common Stockholders (2016 - 2025)

PAVmed's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$1.8 million for Q4 2025.

• In Q4 2025, Net Income towards Common Stockholders fell 236.11% year-over-year to -$1.8 million; the TTM figure through Dec 2025 stood at -$3.8 million (up 88.34% YoY), while the FY2025 annual figure was -$3.8 million, down 111.81% from the prior year.
• Net Income towards Common Stockholders was -$1.8 million for Q4 2025 at PAVmed, up from -$6.3 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $17.7 million in Q1 2025 to a low of -$26.2 million in Q3 2022.
• Historically, Net Income towards Common Stockholders has averaged -$12.8 million across 5 years, with a median of -$14.6 million in 2023.
• Biggest YoY gain for Net Income towards Common Stockholders was 177.65% in 2025; the steepest drop was 236.11% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$17.3 million in 2021, then slipped by 18.79% to -$20.5 million in 2022, then gained by 22.54% to -$15.9 million in 2023, then jumped by 108.46% to $1.3 million in 2024, then tumbled by 236.11% to -$1.8 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$1.8 million (Q4 2025), -$6.3 million (Q3 2025), and -$13.3 million (Q2 2025), per Business Quant data.